利爾化學(002258.SZ):綿陽基地其他生產線正在逐步恢復生產
格隆匯10月27日丨利爾化學(002258.SZ)公佈,於2021年7月17日披露了《關於收到現場處理措施決定書的公吿》(2021-042號),根據綿陽市應急管理局下發的《現場處理措施決定書》((綿)應急現決[2021]支108號),公司綿陽生產基地暫時停止生產。2021年9月29日,公司披露了《關於公司綿陽基地停產的進展公吿》(2021-042號),公司部分生產線已恢復了生產。
截至公吿披露日,上次已復產的生產線運行正常,除氟環唑、炔草酯以外,公司綿陽基地其他生產線正在逐步恢復生產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.